James Wright

TL;DR: Developing and clinical translation of a targeted polymeric nanoparticle (TNP) containing the chemotherapeutic docetaxel (DTXL) for the treatment of patients with solid tumors and initial clinical data indicated that DTXL-TNP displays a pharmacological profile differentiated from sb-DTXL.

TL;DR: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol as mentioned in this paper.

TL;DR: In this article, a biocompatible nanoparticle composition comprising a plurality of noncolloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, was disclosed.

TL;DR: The present disclosure generally relates to therapeutic nanoparticles as discussed by the authors, which may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.

TL;DR: In this article, the present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures, and other aspects of the invention include methods of making such nanoparticles.